These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 27198487)
21. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer. Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337 [TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. Buttigliero C; Pisano C; Tucci M; Vignani F; Bertaglia V; Iaconis D; Guglielmini P; Numico G; Scagliotti GV; Di Maio M Acta Oncol; 2017 Apr; 56(4):555-562. PubMed ID: 28068151 [TBL] [Abstract][Full Text] [Related]
23. Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. Mehra N; Sharp A; Lorente D; Dolling D; Sumanasuriya S; Johnson B; Dearnaley D; Parker C; de Bono J Clin Genitourin Cancer; 2017 Dec; 15(6):678-684.e1. PubMed ID: 28606735 [TBL] [Abstract][Full Text] [Related]
24. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831 [TBL] [Abstract][Full Text] [Related]
25. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. Tait C; Moore D; Hodgson C; Brown M; Morris T; Growcott J; Malone M; Hughes A; Renehan A; Clarke NW; Dive C BJU Int; 2014 Dec; 114(6b):E70-E73. PubMed ID: 24589330 [TBL] [Abstract][Full Text] [Related]
26. Predictors of poor response to first-generation anti-androgens as criteria for alternate treatments for patients with non-metastatic castration-resistant prostate cancer. Fukuoka K; Teishima J; Nagamatsu H; Inoue S; Hayashi T; Mita K; Shigeta M; Kobayashi K; Kajiwara M; Kadonishi Y; Tacho T; Matsubara A Int Urol Nephrol; 2020 Jan; 52(1):77-85. PubMed ID: 31552574 [TBL] [Abstract][Full Text] [Related]
27. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
28. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772 [TBL] [Abstract][Full Text] [Related]
29. Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. Schlack K; Krabbe LM; Fobker M; Schrader AJ; Semjonow A; Boegemann M Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618028 [TBL] [Abstract][Full Text] [Related]
30. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Omlin A; Pezaro C; Mukherji D; Mulick Cassidy A; Sandhu S; Bianchini D; Olmos D; Ferraldeschi R; Maier G; Thompson E; Parker C; Attard G; de Bono J Eur Urol; 2013 Aug; 64(2):300-6. PubMed ID: 23313031 [TBL] [Abstract][Full Text] [Related]
31. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Danila DC; Anand A; Schultz N; Heller G; Wan M; Sung CC; Dai C; Khanin R; Fleisher M; Lilja H; Scher HI Eur Urol; 2014 Jun; 65(6):1191-7. PubMed ID: 23954088 [TBL] [Abstract][Full Text] [Related]
32. The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone. Boegemann M; Schlack K; Thomes S; Steinestel J; Rahbar K; Semjonow A; Schrader AJ; Aringer M; Krabbe LM Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208664 [TBL] [Abstract][Full Text] [Related]
33. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222 [TBL] [Abstract][Full Text] [Related]
34. Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer. Kwan EM; Fettke H; Docanto MM; To SQ; Bukczynska P; Mant A; Pook D; Ng N; Graham LK; Mangiola S; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Horvath LG; Azad AA Eur Urol Focus; 2021 Jan; 7(1):63-70. PubMed ID: 31103601 [TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of time to prostate-specific antigen (PSA) nadir and its relationship to survival beyond time to PSA nadir for prostate cancer patients with bone metastases after primary androgen deprivation therapy. Teoh JY; Tsu JH; Yuen SK; Chan SY; Chiu PK; Lee WM; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK Ann Surg Oncol; 2015 Apr; 22(4):1385-91. PubMed ID: 25234025 [TBL] [Abstract][Full Text] [Related]
36. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481 [TBL] [Abstract][Full Text] [Related]
37. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964 [TBL] [Abstract][Full Text] [Related]
38. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696 [TBL] [Abstract][Full Text] [Related]
39. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Carton E; Noe G; Huillard O; Golmard L; Giroux J; Cessot A; Saidu NE; Peyromaure M; Zerbib M; Narjoz C; Guibourdenche J; Thomas A; Vidal M; Goldwasser F; Blanchet B; Alexandre J Eur J Cancer; 2017 Feb; 72():54-61. PubMed ID: 28027516 [TBL] [Abstract][Full Text] [Related]
40. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]